Aptamers for SARS-CoV-2
Creative Biolabs has successfully developed Aptamers for SARS-CoV-2 with high affinity. Creative Biolabs actively invests in aptamer development to assist researchers to better understand the characteristics of SARS-CoV-2 and drug development.
Complement, as the traditional defense line of innate immunity, has a broad range of physiologic functions, including the opsonization of microbial pathogens with C1q or mannose-binding lectin (MBL), the induction of mast cell degranulation via soluble anaphylatoxins C3a and C5a, the attraction of inflammatory cells, the cytolysis mediated by the membrane attack complex (MAC).
Beyond immune defense, the complement system directs the maintenance of tissue homeostasis and cellular integrity as well as in tissue regeneration. Moderate activation of the complement system has unassailable beneficial functions for our organism, but excessive activation of the system may lead to uncontrolled self-tissue damage and various diseases. Now considerable evidence suggests that the complement plays an important role in the pathophysiology of cardiovascular disease (CVD), including:
CVD is a major clinical manifestation of cardiometabolic disorders, which is characterized by critically narrowing (stenosis) or occlusion (atherothrombosis) of blood vessels, including the heart and peripheral or cerebral vessels. The complement system is evaluated to partake in key processes of CVD, such as endothelial dysfunction, atherosclerosis, and impaired regulation of coagulation and fibrinolysis.
Fig.1 The key processes and complement associated role in CVD. (Hertle, 2014)
The complement system plays a central, causative role in the pathogenesis of cardiovascular disease. So the complement components have the ability for genetic risk prediction and clinical trials of novel therapies.
Creative Biolabs' comprehensive complement platform offers a great number of complement-related products in a rapid and cost-effective manner. If you are interested, please feel free to contact us for more details.
1. Hertle, E.; et al. (2014). The complement system in human cardiometabolic disease. Molecular immunology. 61(2), 135-148.